Select Bibliography

Filter by any of these (after searching):

Aggarwal, Rahul

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 4 items

A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: an Alliance Foundation trial (AFT-19)

Aggarwal, Rahul , Eggener, Scott , Chen, Ronald , Heller, Glenn ... - ASCO - J Clin Oncol - 2018

Abstract - No-Endpoint - Trial-Description-Only - GU - AFT-19

The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy with Docetaxel in Patients with Metastatic Castrate Resistant Prostate Cancer: Results from a Retrospective Analysis of a Randomized Phase 3 Clinical Trial (CALGB 90401) (Alliance)

Aggarwal, Rahul , Halabi, Susan , Kelly, William Kevin ... - - Cancer - 2013

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401

Baseline Characteristics Associated with PSA Progression-Free Survival in Patients (pts) with High-Risk Biochemically Relapsed Prostate Cancer: Results from the Phase 3 PRESTO study (AFT-19)

Aggarwal, Rahul , Heller, Glenn , Hillman, David , Xiao, Han ... - ASCO GU - J Clin Oncol - 2023

Abstract - Secondary-not-in-original - Primary - GU - AFT-19

PRESTO: A Phase 3, Open-Label Study of Androgen Annihilation in Patients with High-Risk, Biochemically Relapsed Prostate Cancer (AFT-19)

Aggarwal, Rahul , Heller, Glenn , Hillman, David , Xiao, Han ... - ESMO - Ann Oncol - 2022

Abstract - Primary - Primary - GU - AFT-19